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Abstract:  Single cycle reporter viruses that preserve the majority of the HIV-1 
genome, long terminal repeat-promoted transcription and Rev-dependent structural 
protein expression are useful for investigating the viral life cycle. Reporter viruses 
that encode the viral proteins in cis in this way have been lacking for feline 
immunodeficiency virus (FIV), where the field has used genetically minimized 
transfer vectors with viral proteins supplied in trans. Here we report construction and 
use of a panel of single cycle FIV reporter viruses that express fluorescent protein 
markers. The viruses can be produced to high titer using human cell transfection and 
can transduce diverse target cells. To illustrate utility, we tested versions that are (+) 
and (-) for OrfA, an FIV accessory protein required for replication in primary 
lymphocytes and previously implicated in down-regulation of the primary FIV entry 
receptor CD134. We observed CD134 down-regulation after infection with or without 
OrfA, and equivalent virion production as well. These results suggest a role for FIV 
proteins besides Env or OrfA in CD134 down-regulation.  
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1. Introduction  
Initial analyses of a retrovirus typically involve monitoring productive replication of clinical 
isolates or passaged viral strains. To analyze the viral replication process more precisely, 
genetically defined full-length infectious molecular clones are utilized. However, proper 
interrogation of specific life cycle steps — entry, reverse transcription, nuclear import, 
integration, assembly, etc. — typically requires a replication-defective system in which single 
infection cycles can be assessed quantitatively and viral production (late events) can be separated 
experimentally from the infection events spanning entry to integration (early events). Reporter 
genes that can be monitored more readily than viral antigens can be inserted and ease of 
containment may be enhanced. Two types of retroviral vector systems are used for this purpose. 
One characteristically expresses most retroviral proteins in cis (reporter viruses) and the other in 
trans (typical gene therapy vectors). Each has specific advantages that depend upon the 
experimental goal. In the case of HIV-1, split-component systems in which the genome is a 
minimal transfer vector are readily available for basic and translational research but are preferred 
in the gene therapy setting [1]. For basic virology in which the goal is to analyze the life cycle 
with fidelity to the natural situation, it is often more desirable to use an HIV-1 reporter virus that 
has been rendered minimally replication-defective with a frame-shift or deletion in env. This is 
particularly advantageous if the complex transcription, genomic RNA splicing and protein 
expression cascade that eventuates in Rev-dependent protein accumulation is under study. Either 
HIV-1 Env or a different envelope protein capable of pseudotyping is provided in trans. Since the 
viral nef gene is dispensable for most studies of HIV-1 in cultured cells, its open reading frame 
has traditionally provided an optimal locus for inserting a luciferase or GFP cDNA [2-4]. HIV-1 
reporter viruses of this kind have facilitated a large number of basic research studies in the past 
two decades. 
Non-primate lentiviruses such as FIV, EIAV and Visna provide informative comparative 
models, and in the case of FIV, AIDS can be studied. For these lentiviruses, minimal vector 
systems have been engineered [5]. FIV vectors have recently seen markedly increased use in basic 
virology studies conducted by HIV investigators, most prominently for investigation of species-
specific post-entry restriction mechanisms [6-31]. However, reporter viruses analogous to those 
available for HIV-1 have been lacking. One main reason is that an optimal approach for marker 
gene insertion into a full-length or env-minus FIV genome is less evident than it is for the primate 
lentiviruses. FIV lacks a nef gene or other accessory gene-encoding open reading frame similarly 
situated at the 3’ end of the genome. Here we describe the construction and initial use of FIV 
reporter viruses. 
2. Results  
The virus design strategy needed to take into account two main considerations. First, highly 
transfectable feline cell lines conducive to high titer virus production are not available (i.e., no 
feline equivalent to commonly employed 293T or COS producer cells). Second, there are several 




primate lentiviruses. The viruses we constructed here (Figure 1A) are based on the previously 
reported pCT5 modification [5,32] of the FIV 34TF10 molecular clone [33]. In the parental 
plasmid pCT5, the essential modification of the FIV genome is that the promoter-containing 5’ 
U3 element is replaced by the human cytomegalovirus immediate early gene (hCMV) promoter. 
The fusion is at the TATA box located just upstream of the 5’ R repeat [5,32] (Figure 1A). 
Because the FIV U3 displays minimal promoter activity in human cells, this modification permits 
genetically defined FIV genomes and their encoded proteins to be produced at high yield by 
transfection of well-characterized human cell lines, e.g., 293T cells [5,32]. The other main 
genomic organization constraint to be circumvented is that no open reading frame analogous to 
nef exists in FIV. Additionally in contrast to the primate lentiviruses, the indispensable second 
exon of Rev overlaps with the polypurine tract and the 3’ U3 element. Therefore, the 3’ end of the 
FIV genome does not provide a natural insertion point for a marker gene.  
To address this issue, we instead expressed the marker proteins eGFP or mCherry as 2A 
peptide-linked in-frame insertions in the central region of env (Figure 1A). 2A peptides, originally 
identified in foot-and-mouth disease virus [35], are 18-22 amino acid peptides that contain a 
conserved Asp-Val/Ile-Glu-X-Asn-Pro-GlyPro motif [36]. This extremely rare sequence 
mediates ribosomal skipping and co-translational cleavage between the terminal Gly and Pro 
(arrow, previous sentence) without affecting translation of the downstream (“2B”) portion of the 
polypeptide. Here the 19 amino acid porcine teschovirus-1 2A (P2A) peptide was used and 
inserted such that a segment encoding 152 N-terminal amino acids of FIV SU are upstream. This 
strategy avoids intrusion of the marker gene upon either exon of Rev or the RRE, and it moreover 
preserves the vif and orfA genes for experimental analysis. Microscopy showed that cells 
transduced with these viruses were homogeneously fluorescent for GFP or mCherry (data not 
shown). Consistent with this, immunoblotting showed that the P2A peptide resulted in production 
of free fluorescent proteins (Figure 1B). We then created OrfA (+) and (-) versions of each of the 
eGFP and mCherry reporter viruses. We did so by first repairing in pCT5 the premature stop 
codon retained from the parental provirus. The OrfA (+) version pCT5 is termed pCT5
A+.  




Figure 1. Virus design and testing of biological activity of restored OrfA in replicating 
FIV. (A) Virus genome arrangements. U3: 3’ unique element. U5: 5’ unique element. R: 
repeat element. PPT: polypurine tract. 2A: porcine teschovirus 2A peptide. CMV: human 
cytomegalovirus immediate early gene promoter. efs: envelope frame shift (black 
arrowhead). CT5efs has a frameshift in env, which was used as the insertion point for the 
2A peptide as well. Env*: N-terminal Env protein fragment resulting from the frame 
shift. Open arrowheads indicate the GFP and mCherry stop codons (the env mRNA 
fragment distal to the stop codons is untranslated). (B) Immunoblotting demonstrates that 
the P2A peptide results in co-translational cleavage and generation of free GPF (left) and 
mCherry (right). Lane 1: cells expressing eGFP or mCherry; Lane 2: untransfected 
negative control; Lanes 3 and 4: reporter viruses. 293T cell lysates were harvested 48 
hours after transfection and blotted with antibodies to GFP or mCherry. (C-F) Replication 
of viruses produced from CT5 and CT5
A+ in primary feline PBMC, feline T-cell lines 
Mya-1 and FetJ, and CrFK cells. Cells were not induced with any additional agents, such 
as soluble CD134 [34] with the exception that Mya-1 cells were maintained with human 
IL-2 as described in Section 3. Error bars represent standard deviation of duplicate 
measurements. 




Figure 1. cont. 
 
Figure 2. Virus production. Supernatant reverse transcriptase activities of the 
different reporter viruses. For vector GiNSIN, the source of RT activity is the 
packaging plasmid pFP93 used to trans-package the transfer vector [6,40]. 
Background RT activities determined in supernatants of un-transfected control cells, 
which were between 0.1–1 % of transfected cell supernatant values, were subtracted 
before graphing. Error bars represent standard deviation of duplicate measurements. 




orfA is required for FIV replication in feline PBMCs and some T cell lines but not CrFK cells 
[37-39]. To verify that the orfA allele we generated by conversion of the premature stop codon to 
a tryptophan codon is functional, primary feline PBMCs, the feline T-cell lines FeT-J and Mya-1, 
and CrFK cells were infected with pCT5 and pCT5
A+-generated virus particles at equivalent MOI. 
The greatest disparity was observed in PBMC, where the CT5-generated virus did not replicate 
productively while CT5
A+ did so robustly (Figure 1C). In the two lymphoid cell lines the CT5
A+ 
virus achieved higher peak levels (Figure 1D,E). These results confirm the biological activity of 
the repaired orfA (+) allele and previous reports that it is required for replication in feline PBMC. 
The active orfA allele was then incorporated into the reporter viruses by exchange of restriction 
fragments containing the gene. Supernatant RT activities produced by transient transfection of 
pCT5, pCT5-cherry, pCT5-GFP and the respective OrfA+ versions were equivalent (Figure 2) 
and at 10
7 to more than 10
8 RT units per ml are also comparable to those produced by FIV 
packaging plasmid pFP93 [6,40]. Thus, the marker gene insertions did not detectably impair late 
events from transcription through splicing, Rev-dependent protein production and budding, and 
OrfA was neutral in this regard as well.  
Reporter virus titers were then determined by flow cytometry for GFP or mCherry (Figure 3A-
C). They ranged between 10
7 and 10
9 transducing units per ml in several feline cell lines and were 
equivalent to standard FIV vectors generated with pFP93 and the minimal FIV transfer vector 
GiNSIN [40-43].  
Figure 3. Reporter virus titers on (A) CrFK; (B) G355-5; and(C) FetJ cells. Viruses 
and the GiNSIN vector were pseudotyped here and in following experiments with 
vesicular stomatitis virus glycoprotein G (VSV-G). Error bars represent standard 
deviations of duplicate measurements. 
 
 
Multiple viral life cycle functions have been provisionally assigned to OrfA in previous 
studies, including a promoter transactivation role analogous to that of the HIV-1 Tat protein, cell 
cycle arrest induction, protein ubiquitination, CD134 down-regulation  and a role in virus 
assembly and particle formation [39,44-49]. Most recently, Hong et al. reported that OrfA 




express CD134 (GFox cells) [46]. To initiate our own analyses of the role of this viral accessory 
protein, we independently generated CrFK cells that express feline CD134 (Figure 4).  
We then infected them with serial dilutions of RT activity-normalized VSV-G pseudotyped 
reporter viruses. At 72 hours, cells were examined by flow cytometry for mCherry and CD134 
surface expression (Fig 4A). Transduction with a minimal trans-packaged lentiviral vector that 
encodes only mCherry and no viral proteins, was done in parallel as a control. Surface CD134 
down-regulation was observed with both CT5-cherry and CT5-cherry
A+. It was slightly greater 
with the latter. In contrast the vector encoding mCherry alone caused no CD134 down-regulation 
(Figure 4A).  
CrFK-CD134 cells were then transduced at equivalent MOIs with CT5efs and CT5efs
A+ 
(Figure 4B). These two viruses do not carry reporter gene insertions but are Env (-) by virtue of a 
frameshift caused by a 29 nt insertion in env (Figure 1A). Viral protein expression was assessed 
by western blotting for FIV Gag/Pol expression in the target cells and this was equivalent for the 
two viruses (Figure 4C). Surface CD134 down regulation was observed with both viruses, but 
there was no significant difference between the OrfA (+) virus compared to the OrfA (-) virus, 
even at an MOI of 2.6 (90% of cells infected). These experiments suggest that viral determinants 
other than Env or OrfA contribute to down-regulation of CD134.  




Figure 4. Testing of OrfA (+) and (-) reporter virus. (A) CrFK-CD134 cells were 
derived as described in the Experimental Section and the stable cell line was infected 
with increasing amounts of each CT5cherry or CT5-cherry
A+ reporter virus. Lentiviral 
vector TsinCherry [25], which expresses mCherry under control of the hCMV 
promoter but encodes no viral proteins, was used as a control. Flow cytometry for 
CD134 surface expression was performed at 72 hours. (B) 30,000 CrFK-CD134 cells 
were infected with CT5efs and CTefs
A+ viruses at equivalent MOI (0.5 and 2.6). MOI 
was calculated by pre-titration on CrFK-CD134 cells with the focal infectivity assay 
of Remington et al. [50]. Flow cytometry for CD134 surface expression was 
performed at 72 hours. Error bars represent standard deviations of duplicate 
measurements. (C) Immunoblotting for FIV Gag/Pol (top blot) and tubulin (bottom 
blot) in lysates of the cells shown in panel B (MOI = 2.6). Numbers indicate MW 
markers (kDa). 
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3. Experimental Section  
3.1 Cell lines.  
Crandell feline kidney (CrFK) cells and FeT-J cells were obtained from the ATCC. Feline KE-
R cells were kindly provided by C. Münk (Heinrich Heine University, Düsseldorf). G355-5, Mya-
1, and murine L2.23 cells, which produce human IL-2 used for culture of PBMC and Mya-1 cells, 
were gifts from T. Miyazawa (Kyoto University, Japan). CrFK, KE-R and G355-S cells were 
maintained in Dulbecco’s modified Eagle medium (DMEM) with 10% heat-inactivated fetal calf 
serum (FCS), penicillin/streptomycin and L-glutamine. FeT-J and Mya-1 were maintained in 
RPMI with 10% FCS and penicillin-streptomycin and L-glutamine with additions for FeT-J (0.1% 
-mercaptoethanol) and Mya-1 (20% FCS, 10% D-glucose, 1% sodium bicarbonate, 1% sodium 
pyruvate, IL-2, and 1% non-essential amino acids). Feline peripheral blood mononuclear cells 
(PBMC) were obtained by Ficoll centrifugation from whole blood and were cultured in RPMI 
medium supplemented with 10% FCS, 2 mM glutamine, 1
 mM sodium pyruvate, essential and 
nonessential amino acids,
 10 mM HEPES, 0.05 mM β-mercaptoethanol, phytohemagglutinin
 E 
(PHA-E; 2 µg/ml), and IL-2. 
3.2 Generation of CrFK-CD134 cells.  
A stable feline CD134-expressing cell line (CrFK-CD134) was derived by transducing CrFK 
cells with a pDONAI-derived gammaretroviral vector that encodes CD134 ([51]; kind gift of B. 
Willett, University of Glasgow). For this purpose VSV-G-pseudotyped retroviral vector particles 
were prepared by 293T cell transfection with Moloney murine leukemia virus packaging plasmid 
pHIT60 [52] and a VSV-G expression plasmid. The transduced cells were selected in 800µg/ml 
G418 and single cell clones were derived by limiting dilution. Cell surface expression was 
assessed before and after cloning by flow cytometry with anti-CD134 (MCA 2568A488T, AbD 




3.3 Construction of pCT5 based reporter vectors.  
Overlap extension PCR was first used to repair the premature stop codon in the pCT5 orfA 
gene (an alternative name for this gene is orf2). Outer primers were 
GTTTTACCTCTTGAATTTCGTTCC and GATTGGCAGGTAAGTAGAAGACTC, and inner 
primers were CTATATCTCCAAAATAATCCCTGCAGTAATCTAATAGCTTTGTCCC and 
ATTACTGCAGGGATTATTTTGGAGATATAGATTTAAGAAACCC. This follows the 
strategy of Waters et al. [38] to change the orfA premature stop codon to TGG (Trp) (Figure 1A). 
This construct was called pCT5
A+. We then exchanged the KpnI-BstB1 segment spanning orfA 
from pCT5
A+ into pCT5efs; the latter is a version of pCT5 in which a short (29 nt) insertion in env 
generates a frameshift [53]. This yielded pCT5efs
A+. Next, we introduced reporter genes encoding 
GFP and mCherry into the FIV envelope such that each was in frame with env and was preceded 
by porcine teschovirus 2A (P2A) peptide (ATNFSLLKQAGDVEENPGP) [36].  pCT5 was 
digested with BglII and the smaller fragment was ligated and called pCT5deltaBglIIS, the larger 
fragment (pCT5deltaBglIIL) was treat with calf intestinal phosphatase and kept for use as a 
backbone for reinsertion. A P2A-gfp amplicon was synthesized by PCR using a pre-existing 
template (data not shown) with the primers sP2Agfp (TTTCCTAGGAGCCACGAA 
CTTCTCTCTGTTAAAGC) and aP2Agfp (AAACTAGTTTACTTGTACAGCTCGTCCATG 
CCGAG) and was inserted into pCT5deltaBglIIS between AvrII and SpeI; this strategy results in 
replacement of 1.56 kb of env with the P2A-GFP insert but does not intrude upon any other 
reading frames or known cis-acting elements, such as either Rev exon or the RRE and was 
therefore predicted to not interfere with the Rev-dependent splicing program of FIV. This 
intermediate was then digested with BglII and ligated with PCT5deltaBglIIL to generate the 
reporter virus pCT5-GFP. The segment between BlpI and KpnI was exchanged into pCT5
A+ to 
obtain pCT5-GFP
A+. pCT5-Cherry and pCT5-cherry
 A+ were constructed analogously using 
primers sP2Acherry (TTCCTAGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGA 
GACGTGGAAGAAAACCCCGGtCCTATGGTGAGCAAGGGCGAGG) and aP2Acherrry 
(AAACTAGTTTACTTGTACAGCTCGTCC). 
3.4 Single-round FIV reporters and full length replicating FIV production.  
VSV-G pseudotyped reporter virus particles were produced by transfection of 293T cells as 
described [6,40]. Supernatants were harvested 48h later, filtered (0.45 µM), concentrated by 
ultracentrifugation over a sucrose cushion in a swinging bucket SW32Ti rotor at 25,000 rpm for 2 
h, aliquoted and frozen at –80° C. Replication competent virus production was performed by 
293T cell transfection of pCT5
  and pCT5
A+. Reverse transcriptase (RT) activities were 
determined using a 
32P-based microtiter plate assay as described previously [6] and titration was 
performed on CrFK cells using a focal infectivity assay [32]. Mean RT activity +/- s.d. from 
duplicate measurements was calculated for each sample. To assess GFP and m-cherry expression, 




3.5 Immunoblotting.  
Equal number of cells uninfected or infected with either CT5efs or CT5efs
A+ viruses at an MOI 
of 2.6 were lysed in RIPA buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% sodium dodecyl 
sulfate, 1% NP-40, 150 mM Tris-HCl, pH 8.0) with protease inhibitors (Complete mini; 
Boehringer). For Figure 1B, cells were processed similarly after transfection with the reporter 
viruses or plasmids that express only GFP or mCherry under transcriptional control of the hCMV 
promoter. The lysates were boiled in Laemmli buffer with β-mercaptoethanol for 10 min, 
electrophoresed in 10% Tris-HCl gels (Bio-Rad), and transferred over one hour to a PVDF 
menbrane (Bio-Rad). The blocked membrane was incubated with serum from a cat infected with 
FIV PPR (kind gift of S. VandeWoude) or anti α-tubulin antibodies (Sigma) for one hour at 
1:1000 dilution, then washed with Tris-buffered saline–Tween 20 (TBST) three times for 7 min 
each. Afterward, membranes were incubated for 1h at room temperature with the secondary goat 
anti-cat at 1:1000 (MP Biomedicals 55293) and goat anti-mouse horseradish peroxidase 
(Calbiochem), at 1:4000. After washing with TBST 3 times for 10 min each, membranes were 
incubated in SuperSignal West Pico chemiluminescent substrate (Pierce) for 1 to 2 min and 
exposed to film. For Figure 1B, the primary antibodies used were monoclonal mouse anti-GFP 
(Clonetch) and polyclonal rabbit anti-mCherry at 1:5000 for 1h; while the secondary antibodies 
were goat anti-mouse and anti-rabbit horseradish peroxidase (Calbiochem), at 1:4000 for 1h.  
4. Discussion and Conclusions 
We describe a set of four FIV reporter viruses in which fluorescent proteins are expressed as 
2A peptide fusions within Env. The reporters can be produced at high titer using standard 
transient transfection methods in the primate cell lines that are widely used for genetically-defined 
virus and reporter virus production. This is an advantage since there are no feline cell lines that 
are readily transfected and we have previously shown that the only block to FIV virion production 
in human cells is the inactive U3 element promoter [5,32]. Alternative marker gene arrangements 
may be feasible for FIV but the present insertion into env preserved viral production and 
infectivity. 
These reporter viruses add to the experimental armamentarium by allowing the FIV life cycle 
to be assessed in the same manner as HIV-1 has been assessed for years [2,3,25]. To illustrate 
capacity for addressing a specific virological question, we initiated studies with OrfA (+) and (-) 
reporters. Besides Vif, for which a clear role in APOBEC3 antagonism has been identified 
[10,11,15], OrfA is the only other known FIV accessory protein. Its function or functions in the 
FIV life cycle are not clear at present. We confirm the prior reports [37-39] that this protein is 
needed for FIV to replicate in feline PBMC (Figure 1C) and show that it also enhances replication 
in feline T cell lines (Figure 1D,E). As Vif, Vpx, Nef and Vpu have been shown in the primate 
lentiviruses to function mainly to counter species-specific restriction factors [54], it is reasonable 
to conjecture that OrfA could be involved in such activities. Several reports have also described 
primate lentivirus Tat protein-analogous (LTR-transactivating) function [45,48], effects on 




regulation function [46]. While this protein has so far received relatively limited study, lentiviral 
accessory protein multi-tasking would not be surprising. For example, HIV-1 Vpu mediates 
primary receptor (CD4) down-regulation [55] and also counteracts the restricting activity of BST-
2/Tetherin [56]. Whether or not effects on CD134 are a main contributor to the OrfA requirement 
for PBMC replication is deserving of further study. To apply the reporter viruses to this 
phenomenon, we generated CD134 (+) and (-) cell lines and tested OrfA(+) and (-) reporter virus 
infection. Our results raise the possibility that CD134 down-regulation is not mainly a 
consequence of OrfA but may result from expression of other viral proteins. The reporter viruses 
will facilitate additional work in this area. We also did not detect a specific effect of OrfA on the 
viral production and assembly phase in transfected 293T cells (Figure 2).  
In summary, the present work makes available a set of FIV reporter viruses that can be used 
for single cycle analyses of the FIV life cycle while expressing all viral proteins but Env in cis.  
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